OverviewSuggest Edit

Delcath Systems is an interventional oncology company which focuses on the treatment of primary and metastatic liver cancers. The Company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. 

TypePublic
Founded1988
HQNew York, US
Websitedelcath.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2018)43(-6%)
Revenue (FY, 2017)$2.7 M(+37%)
Share Price (Sept 2020)$9.4 (-6%)
Cybersecurity ratingBMore

Key People/Management at Delcath Systems

John Purpura

John Purpura

Interim Chief Executive Officer, Executive Vice President, Global Head of Operations
Roger G. Stoll

Roger G. Stoll

Chairman
John R. Sylvester

John R. Sylvester

Director
Elizabeth Czerepak

Elizabeth Czerepak

Director
Gil Aharon

Gil Aharon

Director
Steven Salamon

Steven Salamon

Director
Show more

Delcath Systems Office Locations

Delcath Systems has offices in New York, Queensbury and Galway
New York, US (HQ)
Paramount Plaza, 1633 Broadway 22nd Floor, Suite C
Queensbury, US
566 Queensbury Ave
Galway, IE
Unit 19 Mervue Business Park
Show all (3)

Delcath Systems Financials and Metrics

Delcath Systems Revenue

Delcath Systems's revenue was reported to be $2.72 m in FY, 2017
USD

Net income (Q2, 2020)

(4.3m)

EBIT (Q2, 2020)

(4.3m)

Market capitalization (23-Sept-2020)

36.8m

Closing stock price (23-Sept-2020)

9.4

Cash (30-Jun-2020)

16.0m

EV

23.9m
Delcath Systems's current market capitalization is $36.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

346.0k790.0k1.1m1.7m2.0m2.7m

Revenue growth, %

118%63%

Cost of goods sold

39.0k464.0k291.0k462.0k550.0k701.0k1.0m719.0k

Gross profit

307.0k326.0k778.0k1.3m1.4m2.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

106.0k39.0k381.0k72.0k310.0k251.0k217.0k444.0k466.0k399.0k370.0k511.0k435.0k743.0k584.0k684.0k702.0k858.0k824.0k

Cost of goods sold

31.0k332.0k23.0k93.0k66.0k50.0k133.0k137.0k90.0k111.0k150.0k112.0k219.0k135.0k172.0k147.0k220.0k233.0k96.0k172.0k172.0k78.0k168.0k

Gross profit

106.0k39.0k350.0k(332.0k)49.0k217.0k185.0k167.0k311.0k329.0k309.0k259.0k361.0k323.0k524.0k449.0k512.0k555.0k638.0k591.0k

Gross profit Margin, %

100%100%92%68%70%74%77%70%71%77%70%71%74%71%77%75%79%74%72%
USDQ2, 2011

Financial Leverage

1.5 x
Show all financial metrics

Delcath Systems Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Delcath Systems Online and Social Media Presence

Embed Graph

Delcath Systems News and Updates

Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors

NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharma, biotech, and ve…

Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-for-700 reverse stock split of the Company’s comm…

Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019

NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chief Financial Office…

Delcath Systems Announces Postponement of Reverse Stock Split

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent notification …

Delcath Systems Announces $20 Million Private Placement

NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (OTCPK: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each Unit consists…

Delcath Systems Frequently Asked Questions

  • When was Delcath Systems founded?

    Delcath Systems was founded in 1988.

  • Who are Delcath Systems key executives?

    Delcath Systems's key executives are John Purpura, Roger G. Stoll and John R. Sylvester.

  • How many employees does Delcath Systems have?

    Delcath Systems has 43 employees.

  • Who are Delcath Systems competitors?

    Competitors of Delcath Systems include OncoStem Diagnostics, CollPlant and PLUS THERAPEUTICS.

  • Where is Delcath Systems headquarters?

    Delcath Systems headquarters is located at Paramount Plaza, 1633 Broadway 22nd Floor, Suite C, New York.

  • Where are Delcath Systems offices?

    Delcath Systems has offices in New York, Queensbury and Galway.

  • How many offices does Delcath Systems have?

    Delcath Systems has 3 offices.